Skip to content

Study · In vitro (cells) · rat · 1993

3 results

Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II.

Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC

The Biochemical journal1 Aug 1993Cited by 54 (Europe PMC)

PMID7688957 (opens in a new tab)PMCIDPMC1134424 (opens in a new tab)DOI10.1042/bj2930713 (opens in a new tab)PepBankPUB-07688957
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat L6 myoblasts, des(1‑3)IGF-I was about 100-fold more potent than des(1-6)IGF-II in the protein-synthesis assay.

    In plain wordsIn cells, des(1‑3)IGF-I stimulated protein synthesis more potently than des(1-6)IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseProtein synthesis potency
    Study

    ratn: not reported in source

    L6 myoblasts
    Comparator
    des(1-6)IGF-II
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Relative protein synthesis potency
    100 fold
    approximately, versus des(1-6)IGF-II

    Source sentences

    Summary
    In the L6-myoblast protein-synthesis assay, the IGF-II analogues, des(1-6)IGF-II and [Arg6]-IGF-II, were slightly more potent than IGF-II but about 10-fold less potent than IGF-I and 100-fold less potent than the respective IGF-I analogues, des(1-3)IGF-I and [Arg3]IGF-I.
    1 context sentence
    Summary · context
    The biological activities of the corresponding analogues of IGF-I and IGF-II were compared in rat L6 myoblasts and H35B hepatoma cells.
  2. 02LabIn vitro (cells)Activity measurement

    In H35 hepatoma cells, des(1‑3)IGF-I inhibited protein breakdown less potently than insulin and [Arg3]-IGF-I but more potently than the other listed IGFs.

    In plain wordsIn cells, des(1‑3)IGF-I inhibited protein breakdown with potency between [Arg3]-IGF-I and [Arg6]-IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    MixedProtein breakdown inhibition potency
    Study

    ratn: not reported in source

    H35 hepatoma cells
    Comparator
    Insulin, [Arg3]-IGF-I, [Arg6]-IGF-II, des(1-6)IGF-II, IGF-I and IGF-II
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In H35 hepatoma cells the anabolic response measured was the inhibition of protein breakdown, and the potency order was insulin >>> [Arg3]-IGF-I > des(1-3)IGF-I > [Arg6]-IGF-II > des(1-6)IGF-II > IGF-I > IGF-II.
    1 context sentence
    Summary · context
    The biological activities of the corresponding analogues of IGF-I and IGF-II were compared in rat L6 myoblasts and H35B hepatoma cells.
  3. 03LabIn vitro (cells)Activity measurement

    In rat cell cultures, des(1‑3)IGF-I showed greatly decreased binding to secreted IGFBPs compared with parent IGF-I.

    In plain wordsIn cells, des(1‑3)IGF-I bound secreted binding proteins less strongly than parent IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGFBP binding
    Study

    ratn: not reported in source

    L6 myoblasts and H35B hepatoma cells
    Comparator
    Parent IGF-I
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, binding of all four analogues to the IGFBPs secreted by L6 myoblasts and H35B hepatoma cells was greatly decreased compared with the parent IGF.
    2 context sentences
    Summary · context
    The growth factors were modelled on two previously characterized variants of IGF-I, des(1-3)IGF-I and [Arg3]-IGF-I, which both show substantially decreased binding to IGFBPs and were expressed as fusion proteins in Escherichia coli.
    Summary · context
    The biological activities of the corresponding analogues of IGF-I and IGF-II were compared in rat L6 myoblasts and H35B hepatoma cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 13:52 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.